150 related articles for article (PubMed ID: 25076334)
1. Phase 1 trials in pancreatic cancer.
Yu E; Saif MW; Huber K
JOP; 2014 Jul; 15(4):326-8. PubMed ID: 25076334
[TBL] [Abstract][Full Text] [Related]
2. First line therapy for metastatic pancreatic cancer.
Jarboe J; Saif MW
JOP; 2013 Jul; 14(4):340-3. PubMed ID: 23846923
[TBL] [Abstract][Full Text] [Related]
3. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the management of pancreatic cancer.
Li J; Saif MW
JOP; 2009 Mar; 10(2):109-17. PubMed ID: 19287102
[TBL] [Abstract][Full Text] [Related]
5. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Strimpakos AS; Saif MW
JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926
[TBL] [Abstract][Full Text] [Related]
6. Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Makrilia N; Syrigos KN; Saif MW
JOP; 2011 Mar; 12(2):110-3. PubMed ID: 21386632
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Saif MW
JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine plus cisplatin in advanced pancreatic cancer.
McWilliams RR; Alberts SR
J Clin Oncol; 2007 Mar; 25(9):1142; author reply 1142-3. PubMed ID: 17369580
[No Abstract] [Full Text] [Related]
9. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Rocha Lima CM; Flores AM
J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
[No Abstract] [Full Text] [Related]
10. Conventional chemotherapy of advanced pancreatic cancer.
Giuliani F; Di Maio M; Colucci G; Perrone F
Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
[TBL] [Abstract][Full Text] [Related]
11. Second-line treatment for pancreatic cancer.
Kaddis N; Saif MW
JOP; 2014 Jul; 15(4):344-7. PubMed ID: 25076339
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation.
Savir G; Huber KE; Saif MW
JOP; 2013 Jul; 14(4):337-9. PubMed ID: 23846922
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Wang Y; Hu GF; Zhang QQ; Tang N; Guo J; Liu LY; Han X; Wang X; Wang ZH
Drug Des Devel Ther; 2016; 10():1961-72. PubMed ID: 27358556
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
15. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
Oettle H; Richards D; Ramanathan RK; van Laethem JL; Peeters M; Fuchs M; Zimmermann A; John W; Von Hoff D; Arning M; Kindler HL
Ann Oncol; 2005 Oct; 16(10):1639-45. PubMed ID: 16087696
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced unresectable pancreatic cancer.
Johung KL; Saif MW; Chang BW
JOP; 2014 Jul; 15(4):329-31. PubMed ID: 25076335
[TBL] [Abstract][Full Text] [Related]
17. Locally advanced pancreatic cancer.
Oikonomopoulos GM; Huber KE; Syrigos KN; Saif MW
JOP; 2013 Mar; 14(2):126-8. PubMed ID: 23474552
[TBL] [Abstract][Full Text] [Related]
18. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.
Kunzmann V; Ramanathan RK; Goldstein D; Liu H; Ferrara S; Lu B; Renschler MF; Von Hoff DD
Pancreas; 2017 Feb; 46(2):203-208. PubMed ID: 27841795
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H; Ioka T; Ikeda M; Ohkawa S; Yanagimoto H; Boku N; Fukutomi A; Sugimori K; Baba H; Yamao K; Shimamura T; Sho M; Kitano M; Cheng AL; Mizumoto K; Chen JS; Furuse J; Funakoshi A; Hatori T; Yamaguchi T; Egawa S; Sato A; Ohashi Y; Okusaka T; Tanaka M
J Clin Oncol; 2013 May; 31(13):1640-8. PubMed ID: 23547081
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
